Clinical trial · Interventional
Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will examine the efficacy of Men Moving Forward (MMF), a four-month community-based lifestyle intervention designed for AA PC survivors. MMF is rooted in the evidence-based Moving Forward lifestyle intervention developed with and for AA breast cancer survivors. This intervention was adapted in collaboration with AA PC survivors. It will offer twice weekly sessions aimed at supporting adherence to the ACS nutrition and physical activity guidelines to promote improved body composition (i.e., decreased adiposity, increased lean mass).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immediate Guided Lifestyle Program Intervention | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Immediate Lifestyle program
- description
- The Intervention will be conducted in cohorts of 15-20. We anticipate there will be 5-6 cohorts over the course of the study. Men assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies, the second hour will be supervised exercise with strength training. The second weekly session will be a one-hour supervised exercise session with strength training. Men will also receive 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
- interventionNames
- Behavioral: Immediate Guided Lifestyle Program Intervention
- type
- OTHER
- label
- Waitlist Control
- description
- In the waitlist control arm, the men will not receive any intervention for 16-weeks. After the 16-week assessment, men randomized to this arm will crossover to the intervention arm.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years and older * Self-identify as Black or African American * Diagnosed with non-metastatic Prostate Cancer (cancer that has NOT spread elsewhere in the body) * Completed all treatments (including Androgen Deprivation Therapy) at least six months prior to enrollment * BMI \> 25 kg/m2 * Able to participate in moderate physical activity as assessed by healthcare provider * Exercise less than the ACS recommended guideline of 150 min/week or 30 min/day. * Fruit and vegetable consumption is less than 5 servings each day. * Lift Weights or engage in strength training less than twice a week. * Can walk continuously for 5 minutes without stopping because of pain or shortness of breath. * Have access to a mobile phone * Approval from Primary Care Provider/Medical Oncologist * Available to attend intervention Exclusion Criteria: * • Does not meet the Inclusion Criteria
References
Publications (2)
- BACKGROUNDAwoyinka I, Tovar M, Young S, Beyer K, Kwarteng J, Knight J, Stolley M. Examining the role of social relationships on health and health behaviors in African American men with prostate cancer: a qualitative analysis. Support Care Cancer. 2024 Feb 21;32(3):178. doi: 10.1007/s00520-024-08363-z. PMID 38381216
- BACKGROUNDAwoyinka I, Sheean P, Papanek P, Flynn KE, Bylow K, Kilari D, Gann P, Banerjee A, Stolley M. Study design and methodologies for the men moving forward lifestyle intervention trial with black prostate cancer survivors. Contemp Clin Trials. 2026 Feb;161:108205. doi: 10.1016/j.cct.2025.108205. Epub 2025 Dec 24. PMID 41453520